Risk Factors and Outcomes Associated with Prolonged Subtherapeutic Anticoagulation with Bivalirudin: A Retrospective Cohort Study.

Libby A Orzel Erik E AbelDanielle M BlaisTzu-Fei WangKyle A PorterPamela K Burcham

Published in: Pharmacotherapy (2019)

Younger age, normal renal function, and nonadherence to the dosing protocol when targeting therapeutic anticoagulation is associated with increased risk of failure to achieve ETA. This confers an elevated risk of thromboembolism when using bivalirudin for the management of HIT or other coagulation disorders.

Keyphrases

atrial fibrillation
risk factors
percutaneous coronary intervention
venous thromboembolism
randomized controlled trial
cancer therapy
acute coronary syndrome
coronary artery disease
type diabetes
adipose tissue
skeletal muscle
weight loss